Hilvo M

No ORCID on file · 4 papers in corpus · active 2016-2021
2021
A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer.
Cancers ·doi:10.3390/cancers13081764

Epithelial ovarian cancer (EOC) generally responds well to oncological treatments, but the eventual development of a refractory disease is a major clinical problem. Presently, there are no prognostic blood-based biomarkers for the stratific…

2018
Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.
British journal of cancer ·doi:10.1038/s41416-018-0270-z

BackgroundPrevious results obtained from serum samples of late-stage, high-grade serous ovarian carcinoma patients showed large alterations in lipid metabolism. To validate and extend the results, we studied lipidomic changes in early-stage…

2017
High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism.
Oncotarget ·doi:10.18632/oncotarget.22076

Ovarian cancer is a very severe type of disease with poor prognosis. Treatment of ovarian cancer is challenging because of the lack of tests for early detection and effective therapeutic targets. Thus, new biomarkers are needed for both dia…

2016
Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.
Cancer research ·doi:10.1158/0008-5472.can-15-2298

Ovarian cancer is a heterogeneous disease of low prevalence, but poor survival. Early diagnosis is critical for survival, but it is often challenging because the symptoms of ovarian cancer are subtle and become apparent only during advanced…